Alnylam Pharmaceuticals | ALNY - Stock


Alnylam Pharmaceuticals reported $97.11M in Stock for its fiscal quarter ending in June of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 108.67M 77.1M Jun/2026
Agios Pharmaceuticals USD 35.75M 665K Jun/2026
Alnylam Pharmaceuticals USD 97.11M 103.04M Jun/2026
Amgen USD 6.22B 34M Jun/2026
Arrowhead Research USD -173.08M 173.08M Dec/2024
BioCryst Pharmaceuticals USD 6.06M 71K Jun/2026
BioMarin Pharmaceutical USD 1.78B 509.3M Jun/2026
Incyte USD 112.54M 3.08M Jun/2026
Ionis Pharmaceuticals USD 50.83M 45.28M Jun/2026
Moderna USD 280M 134M Jun/2026
Neurocrine Biosciences USD 104.2M 39.7M Jun/2026
Novartis USD 6.29B 135M Mar/2026
PTC Therapeutics USD 91.35M 15.79M Jun/2026
Regeneron Pharmaceuticals USD 3.08B 19.3M Jun/2026
Sanofi EUR 23.5B 812M Mar/2026
Sarepta Therapeutics USD 904.27M 96.84M Jun/2026
Takeda JPY 1.45T 50.64B Jun/2026
Ultragenyx Pharmaceutical USD 59M 4M Jun/2026
Vertex Pharmaceuticals USD 1.77B 1.6M Jun/2026